Introduction
============

Severe chronic obstructive pulmonary disease (COPD) has a major adverse impact on quality of life and overall health status, with exercise intolerance being a major complaint. In addition to ventilatory limitations, skeletal muscle dysfunction in COPD also contributes to poor exercise capacity and increased health care utilization.[@b1-copd-8-097] Muscle weakness in COPD may be due to multiple factors, including de-conditioning, systemic inflammation, and oxidant stress.

Vitamin D insufficiency and deficiency is highly prevalent in the general population and observational studies in the elderly have demonstrated a link between poor muscle strength and low blood levels of 25-hydroxyvitamin D (25\[OH\]D), the major circulating vitamin D metabolite.[@b2-copd-8-097],[@b3-copd-8-097] 25(OH)D levels below 50 nmol/L (23 ng/mL) have been associated with increased body sway, indicative of poor strength of muscles required for balance.[@b4-copd-8-097] Additionally, advancing age may be associated with decreased vitamin D receptor expression in skeletal muscle.[@b5-copd-8-097] The authors of a meta-analysis of five randomized controlled trials including 1237 participants concluded that supplemental vitamin D reduced the odds of falling by 22%,[@b6-copd-8-097] and the US Preventative Services Task Force recently recommended vitamin D to prevent falls in at-risk elderly individuals.[@b7-copd-8-097] The mechanisms by which vitamin D modulates muscle function remain poorly understood, although a randomized trial in 96 female stroke survivors showed that vitamin D supplementation increased the number and size of type II (also referred to as "fast twitch") muscle fibers.[@b8-copd-8-097]

Low 25(OH)D levels are also very common in patients with COPD, particularly in severe COPD.[@b9-copd-8-097],[@b10-copd-8-097] We hypothesized that in patients with severe COPD, vitamin D supplementation would improve skeletal muscle function, as measured by the Short Physical Performance Battery (SPPB) score.

Materials and methods
=====================

Participants from the Minneapolis Veterans Affairs Health Care System were recruited as a convenience sample between January 2009 and October 2011 from outpatient pulmonary clinics and an institutional review board-approved database of patients with COPD. The trial was approved by the local institutional review board, and registered at Clinical-Trials. gov prior to enrollment of the first patient (NCT 00914810). All participants provided their written informed consent.

Inclusion criteria included age ≥ 50 years, forced expiratory volume in one second (FEV~1~)/forced vital capacity (FVC) ≤70%, FEV~1~ ≤ 50% of predicted, cigarette smoking history ≥ than 10 pack-years, and ability to ambulate independently or with the use of an ambulatory assist device, such as a cane or walker. Exclusion criteria included use of \>500 IU/day of supplemental vitamin D, primary diagnosis of asthma, uncompensated congestive heart failure, acute myocardial infarction in the 6 months prior to enrollment, estimated glomerular filtration rate ≤ 45 mL/min/1.73 m[@b2-copd-8-097], expected survival ≤ 6 months, malignancy treated with chemotherapy and/or radiation in the past 12 months, previously treated cancer now in relapse, metastatic malignancy, psychiatric disease interfering with the patient's judgment, inability to provide informed consent, and any physical condition or diagnosis which the investigators felt would significantly interfere with assessment of muscle function. Pulmonary rehabilitation was not a specific exclusion criterion, but none of the study participants were enrolled in pulmonary rehabilitation during or prior to the trial, largely due to the existence of pulmonary rehabilitation only as a startup pilot project at our facility when this trial was conducted.

Participants who provided informed consent completed the SPPB and St George's Respiratory Questionnaire (SGRQ), and underwent a blood draw. Participants with a SPPB score of 12/12 were additionally excluded at this stage, due to an inability to improve physical performance any further. Subjects were then randomized, using variable block sizes of 2 or 4, to receive an oral capsule containing either vitamin D~3~ (cholecalciferol), or identical-appearing placebo, to be taken once daily for 6 weeks. Cholecalciferol was provided at a dose of 2000 IU per day, which was the Institute of Medicine Food and Nutrition Board upper intake level for vitamin D at the time of study initiation.[@b11-copd-8-097]

Investigators, study coordinators, and study participants were blinded to treatment allocation. Patients then returned at 6 weeks and once again performed the SPPB, completed the SGRQ, and underwent a repeat blood draw.

Short Physical Performance Battery
----------------------------------

The primary outcome was change in SPPB score over the 6-week treatment period. The SPPB test was developed by the National Institute of Aging, is well standardized and validated in elderly populations,[@b12-copd-8-097],[@b13-copd-8-097] and has been used in numerous previous trials in the elderly as a simple outcome to assess changes in lower body muscle strength.[@b14-copd-8-097] Low SPPB scores in the elderly population are associated with a higher risk of nursing home admission,[@b12-copd-8-097] functional decline and disability,[@b15-copd-8-097],[@b16-copd-8-097] longer hospital length of stay,[@b17-copd-8-097] rehospitalization,[@b18-copd-8-097] and mortality.[@b12-copd-8-097],[@b15-copd-8-097] SPPB scores are lower in COPD patients than in age-matched controls,[@b19-copd-8-097] and lower SPPB scores are associated with decreased quadriceps strength in COPD patients.[@b20-copd-8-097]

The SPPB consists of three maneuvers to assess balance, 4 m gait speed, and chair stands ([Table 1](#t1-copd-8-097){ref-type="table"}). Each of the three performance measures is assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 indicating inability to complete the test. A summary score (range 0--12) is subsequently calculated by adding the three scores. Scores of 0--3, 4--6, 7--9, and 10--12 are, respectively, classified as severe, moderate, mild, and minimal lower extremity limitation.[@b12-copd-8-097] We followed the procedures for administering the SPPB as published[@b12-copd-8-097] and made available online by the National Institute of Aging (<http://www.grc.nia.nih.gov/> branches/ledb/sppb/). We chose the SPPB score over the more conventional pulmonary study outcome of 6-minute walk distance, due to multiple organ effects on 6-minute walk distance, including the pulmonary, cardiac, and skeletal muscle systems, whereas the SPPB is not expected to be affected by cardiac or pulmonary limitations. Therefore, the SPPB focuses on the hypothesized primary organ affected by our vitamin D intervention, ie, skeletal muscle. We also chose SPPB over more conventional skeletal muscle outcomes such as dynamometry, because of the simplicity of administering the test without specialized equipment or training.

St George's Respiratory Questionnaire
-------------------------------------

All participants were asked to complete the SGRQ[@b21-copd-8-097] at baseline and at the end of the 6-week intervention period. The SGRQ is a well validated self-administered questionnaire that measures health-related quality of life specifically related to pulmonary disease. The SGRQ contains 50 questions aimed at three domains, ie, respiratory symptoms, limitations of activity from breathlessness, and the impact of lung disease on social and psychological functioning. The SGRQ is scored on a scale of 0--100, with a score of 100 reflecting the most severe symptoms, limitations, and psychosocial impact of respiratory disease.

Serum samples
-------------

Blood samples were drawn by phlebotomists and centrifuged by research staff at 2200 rpm for 15 minutes. Serum was then stored at -70°C until all participants completed the study. Serum 25(OH)D analysis was performed by the Immunochemical Core Laboratory at the Mayo Clinic (Rochester, MN), using liquid chromatography tandem mass spectroscopy, analysis of which provides values for both 25(OH)D2 (the form generated by ultraviolet irradiation of ergosterol from yeast and present in ergocalciferol-containing supplements) and 25(OH)D3 (the form generated by solar ultraviolet B exposure and present in cholecalciferol-containing supplements). These two results are summed to generate the total 25(OH)D level used in clinical assessments and reported in this study. For 25(OH)D2, intra-assay coefficients of variation are 4.4%, 3.3%, and 4.2% at 14, 41, and 124 ng/mL, respectively, and interassay coefficients of variation are 6.1%, 6.2%, and 4.7% at 15, 43, and 128 ng/mL, respectively. For 25(OH)D3, intra-assay coefficients of variation are 3.8%, 2.4%, and 4.7% at 25, 54, and 140 ng/mL, respectively; interassay coefficients of variation are 6.4%, 6.8%, and 5.0% at 24, 52, and 140 ng/mL, respectively.

Sample size and power calculations
----------------------------------

A clinically meaningful difference in SPPB score is not fully agreed upon, although many consider a change in 1.0 point to be significant.[@b14-copd-8-097] The SPPB has not been widely used in intervention studies among patients with COPD, so a clinically meaningful difference specific to COPD has not been established. At the time of trial planning, there were no published data regarding the standard deviation of SPPB scores over time in patients with COPD. Therefore, we utilized data from an elderly non-COPD population showing a standard deviation of 1.5 SPPB points, and we elected to power this as a pilot study to detect a difference of 1.5 SPPB points between the two treatment arms. Using these assumptions, a study with 80% power and a two-tailed alpha error rate of 0.05 required sample sizes of 17 participants per arm.

Data analysis
-------------

The primary analysis compared 6-week changes in SPPB scores between the two groups (vitamin D supplementation versus placebo). Participants who did not complete the study were not included in the analysis, because we had only baseline pre-randomization data for these participants. Changes in SPPB scores were calculated for each participant, using the 6-week SPPB score and subtracting the baseline SPPB score. We used *t*-tests to compare the mean change in SPPB score in the vitamin D arm compared with the placebo arm. Secondary analyses included 6-week change in SGRQ scores and 25(OH)D levels. Because of imbalances in baseline SPPB and SGRQ scores, we also performed linear regression analyses that included baseline SPPB and baseline SGRQ scores as covariates.

Results
=======

Of 41 participants who provided informed consent, 39 met the study entry criteria and were randomized. During follow-up, two participants withdrew from the placebo group (one because of relocation out of the state, one as a result of family bereavement and unavailability for follow-up) and one participant withdrew from the intervention arm (due to prolonged hospitalization and unavailability for follow-up). A total of 18 participants in each arm attended the 6-week follow-up visit ([Figure 1](#f1-copd-8-097){ref-type="fig"}).

Our participants were all Caucasian males, with a mean age of 68 years and severe COPD ([Table 2](#t2-copd-8-097){ref-type="table"}). Baseline characteristics were reasonably well balanced, given the relatively small sample size. In the intervention arm, compared with placebo, there were fewer active smokers, fewer subjects with coronary artery disease, better SPPB scores, and better SGRQ scores. The baseline SPPB score distribution is shown in [Figure 2](#f2-copd-8-097){ref-type="fig"}.

The overall mean baseline 25(OH)D level was 23.5 ng/mL, with values being similar in the two treatment arms (24.4 ng/mL in the placebo arm versus 22.6 ng/mL in the vitamin D arm; *P* = 0.60). Twenty-six percent of the participants had levels ≥ 30 ng/mL, 30% had levels ≥ 20 ng/mL but \<30 ng/mL, and 41% had levels \< 20 ng/mL. Only two patients had baseline 25(OH)D levels \< 10 ng/mL. Pill counts demonstrated that 99% and 98.5% of the prescribed doses were actually consumed in the placebo and vitamin D arms, respectively.

After 6 weeks of receiving the study drug, the vitamin D supplementation arm experienced a significant increase in mean 25(OH)D levels to a level of 32.6 ± 8.2 ng/mL, while the placebo arm had a mean level of 22.1 ± 10.1 ng/mL. Despite increased 25(OH)D levels in the intervention arm, there were no significant improvements in SPPB or SGRQ scores ([Table 3](#t3-copd-8-097){ref-type="table"}). However, the 95% confidence intervals of these differences did not exclude the possibility of a clinically meaningful difference of 1.0 point in SPPB scores or a clinically meaningful change in SGRQ scores of 4 points.[@b22-copd-8-097] A linear regression model was also performed to adjust for baseline imbalances in SPPB and SGRQ scores and resulted in similar non-significant results ([Table 3](#t3-copd-8-097){ref-type="table"}).

None of the three components of the SPPB (balance, chair stands, gait speed) nor the three domains of the SGRQ (symptoms, activity, impact) were significantly different between treatments. The proportion of patients who had minimal clinically important changes in outcome was not different between the placebo and vitamin D arms for either SPPB (50% and 50%, respectively; *P* = 1.0) or for SGRQ (23.5% and 33.3%, respectively; *P* = 0.70). There were no study-related serious adverse events in either treatment arm.

Discussion
==========

To our knowledge, we provide the first report of a randomized controlled trial piloting the effects of vitamin D supplementation on a primary outcome of physical performance in COPD. Our vitamin D intervention significantly increased 25(OH)D levels by 10.5 ng/mL to a mean level of 32.6 ng/mL, a level widely considered as normal.[@b23-copd-8-097] Despite this significant increase, vitamin D supplementation did not significantly improve SPPB or SGRQ scores. The mean 0.3 point greater improvement in SPPB scores observed in the vitamin D arm had a 95% confidence interval ranging from -0.8 to 1.5 points, so did not exclude the possibility of a meaningful change of 1.0 point in SPPB scores.[@b14-copd-8-097] Likewise, the confidence interval for SGRQ effects did not exclude the potential for a clinically meaningful effect. Based on our data regarding the standard deviation of SPPB scores in COPD, a definitive randomized trial to detect a smaller change in SPPB of 1.0 point would require a sample size of 59 patients in each arm; 259 patients in each arm would be needed to detect an even smaller, but potentially meaningful, SPPB change of 0.5 points.[@b14-copd-8-097] Therefore, a larger randomized controlled trial would be needed in order to draw more definitive conclusions regarding the effects of vitamin D on physical performance and respiratory health status in severe COPD.

We chose to utilize the SPPB score to assess physical performance, specifically lower extremity strength, because of its widespread use in the geriatric literature, standardized application, ease of administration by nonphysiologists, and established relationship with clinically relevant outcomes, such as mortality, in the geriatric literature. Based on mechanistic studies, we also hypothesized that vitamin D would affect the fast, powerful type II muscle fibers more than the type I muscle fibers that affect endurance. Given the focus of the SPPB on three tests of lower extremity skeletal muscle power and strength, the SPPB appeared to be an appropriate outcome measure. Despite the attractive features of the SPPB test, it has not been widely used in COPD trials.

Our study sample had severe COPD, with a mean FEV~1~ of approximately 1 L, yet had SPPB scores considered to reflect only mild lower extremity strength impairment. Therefore, a limitation of our study is that our patient sample may not have been significantly impaired enough to derive a potential vitamin D benefit. It would be reasonable to hypothesize that those with lower baseline SPPB scores might be more likely to benefit from potential skeletal muscle-altering therapies such as vitamin D. Due to the small number of patients with more severe SPPB impairment, we were unable to conduct a subset analysis to explore this hypothesis. However, a previous randomized trial of 176 patients with COPD (mean FEV~1~ 52% of predicted) found that patients randomized to either of two different physical activity interventions experienced improvements in SPPB scores, despite having a near-normal mean baseline SPPB score of 10.6[@b24-copd-8-097] compared with our mean baseline SPPB score of 8.3. These data suggest that COPD patients with high SPPB scores can still derive benefits from interventions targeted at lower extremity strength. Therefore, the mild impairment in baseline SPPB scores in our trial sample is of unclear significance.

Another limitation of our study was the relatively short treatment duration of 6 weeks, which may have been an inadequate amount of time to result in detectable skeletal muscle effects. Vitamin D nuclear receptors have been reported to exist in skeletal muscle, although their exact function is not completely understood. It has been suggested that binding of 1,25 dihydroxyvitamin D to these nuclear receptors causes a cascade of intracellular signaling and gene transcription of mRNA, leading to de novo protein and skeletal muscle synthesis.[@b25-copd-8-097]--[@b28-copd-8-097] It is also postulated that with aging, vitamin D receptor expression decreases and leads to decreased transcription and subsequent decreased skeletal muscle strength.[@b5-copd-8-097] Further, vitamin D receptor polymorphisms are associated with variations in quadriceps strength in both normal subjects and COPD patients.[@b26-copd-8-097],[@b29-copd-8-097] Given that improvements in skeletal muscle from vitamin D likely require formation of de novo muscle fibers, particularly type II muscle fbers,[@b8-copd-8-097] a longer period of supplementation may have been necessary to detect clinical changes, although other short-term randomized trials showed that vitamin D improved body sway after only 8 weeks[@b4-copd-8-097] and decreased falls over 12 weeks.[@b30-copd-8-097] Therefore, the duration of treatment needed to detect muscle function effects is not clear. Although we chose a 6-week duration based on the pilot nature of this study and the short-term studies cited above, longer periods of observation in future studies could improve the ability to detect potential longer-term effects of vitamin D on skeletal muscle function in patients with COPD. We also note recent data suggesting that previous reports of vitamin D receptor presence in skeletal muscle may have been erroneous due to problems with many of the vitamin D receptor detection methods.[@b31-copd-8-097] Such data would suggest that potential vitamin D-mediated skeletal muscle effects, if present, are not mediated by direct effects of vitamin D on skeletal muscle tissue.

Another potential limitation is the dose of vitamin D used. Our dose of 2000 IU/day achieved what is widely considered a normal 25(OH)D level,[@b23-copd-8-097] but commonly used vitamin D thresholds for defining normal, insufficient, or deficient levels are largely based on studies of bone health and parathyroid hormone concentrations. The optimal 25(OH)D level for potential skeletal muscle benefits remains unknown, although in general population observational studies, decrements in SPPB scores are uncommonly seen in patients with 25(OH)D levels \> 30 ng/mL[@b2-copd-8-097],[@b3-copd-8-097] and falls have been prevented in elderly populations with vitamin D supplementation to levels of 26--30 ng/mL.[@b30-copd-8-097],[@b32-copd-8-097],[@b33-copd-8-097] In addition, a randomized trial that administered 500,000 IU of oral vitamin D as a single annual dose resulted in a 3-month 25(OH)D level of 48 ng/mL and an increase in falls during that 3-month period.[@b34-copd-8-097] Therefore, the available data do not suggest additional skeletal muscle benefits at supranormal 25(OH)D levels. Patients with more severe forms of vitamin D deficiency (\<10 ng/mL) might be reasonably expected to derive more benefit from supplementation, but our sample was too small to perform a subgroup analysis of such patients. However, future studies might consider selecting such patients or at least planning prespecified and adequately powered analyses of such subgroups.

Randomized trials should ideally adhere to intent-to-treat analyses of all randomized participants. In our trial, three of 39 randomized participants were unable to return for a follow-up visit and therefore provided no outcome data. As such, we could not perform a strict intent-to-treat analysis of all 39 participants. This is the unfortunate case in studies with exercise outcomes, because participants must return to the study center for these assessments (ie, outcomes cannot be assessed by telephone calls nor chart reviews). While we made significant efforts to get every participant to return, three simply could not do so. While a sensitivity analysis is often done in these scenarios (assuming a best or worst case scenario), with our limited power, we did not feel conclusions from such analyses would be of value. Given that there were only two study visits (ie, no data beyond baseline, preran-domization data), last-observation-carried-forward methods for missing data were not appropriate. The reasons for the dropouts do not seem related to physical performance or vitamin D responses, but we cannot exclude the possibility that the dropouts somehow biased our results.

Lastly, we note that our study sample was limited to Caucasian males, largely because of the demographics of the population at our study center. Therefore, our results cannot be extrapolated to non-Caucasians or females.

While our study had these important potential limitations, we must acknowledge the possibility of vitamin D having no effect on physical performance in patients with COPD. In support of such a hypothesis, a recent post hoc subgroup analysis of 50 COPD subjects, who underwent pulmonary rehabilitation during a randomized trial of vitamin D versus placebo, showed no difference in quadriceps strength in the two arms of the trial.[@b35-copd-8-097] Additionally, recently published data also showed that the association between vitamin D levels and quadriceps strength was present in healthy controls, but not in age-matched or gender-matched patients with COPD.[@b36-copd-8-097] Therefore, while vitamin D supplementation may improve muscle strength in a general elderly population, patients with COPD may have limited or no benefit as a result of mechanisms such as systemic inflammation, regional tissue hypoxemia, oxidative stress, and vitamin D resistance.

Conclusion
==========

In conclusion, in this pilot trial of patients with severe COPD, vitamin D 2000 IU/day for 6 weeks significantly increased serum 25(OH)D levels to a widely accepted normal level of 32.6 ng/mL. Despite this increase, vitamin D supplementation had no major effect on a simple measure of lower extremity physical performance, compared with placebo. Larger, longer-duration trials would be required to assess more definitively the potential effects of vitamin D on physical performance in COPD. However, our data and other recently published data make such an effect seem less likely.
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###### 

Short Physical Performance Battery components and scoring

  -------------------------------------------------------- ----------
  **Balance**                                              
  Side-by-side stand \> 10 seconds                         1 point
  Semi-tandem stand \> 10 seconds                          1 point
  **Tandem stand**                                         
  ≥10 seconds                                              2 points
  3.00--9.99 seconds                                       1 point
  ≤2.99 seconds                                            0 points
  **4 m gait speed**                                       
  Unable to walk                                           0 points
  \>8.70 seconds                                           1 point
  6.21--8.70 seconds                                       2 points
  4.82--6.20 seconds                                       3 points
  \<4.82 seconds                                           4 points
  **Chair stands**                                         
  Unable to perform maneuver or \>60 seconds to complete   0 points
  ≥16.70 seconds                                           1 point
  13.70--16.69 seconds                                     2 points
  11.20--13.69 seconds                                     3 points
  \<11.2 seconds                                           4 points
  -------------------------------------------------------- ----------

###### 

Participant characteristics

                                                            Placebo group (n = 18)   Vitamin D group (n = 18)
  --------------------------------------------------------- ------------------------ --------------------------
  Age, years                                                68 ± 8                   67.6 ± 7
  Male, n (%)                                               18 (100)                 18 (100)
  Caucasian, n (%)                                          18 (100)                 18 (100)
  FEV~1~, L                                                 0.99 ± 0.27              1.09 ± 0.37
  FEV~1~, % predicted                                       31 ± 8                   35 ± 10
  FVC, L                                                    2.42 ± 0.75              2.58 ± 0.63
  FVC, % predicted                                          56 ± 17                  61 ± 13
  Currently smoking, n (%)                                  11 (61)                  7 (39)
  Pack-year smoking history                                 69 ± 42                  72 ± 46
  Coronary disease, n (%)                                   9 (50)                   5 (28)
  Heart failure, n (%)                                      3 (17)                   2 (11)
  Pulmonary hypertension, n (%)                             0                        1 (6)
  Hypertension, n (%)                                       10 (56)                  12 (67)
  Osteoarthritis, n (%)                                     9 (50)                   10 (56)
  Rheumatoid arthritis, n (%)                               0 (0)                    1 (6)
  Living independently, n (%)                               18 (100)                 18 (100)
  Estimated (self-report) hours of sun                      11 ± 9                   10 ± 12
  exposure per week over the last month                                              
  Long-acting beta agonist, n (%)                           17 (94)                  15 (83)
  Inhaled corticosteroid, n (%)                             13 (72)                  15 (83)
  Long-acting anticholinergic, n (%)                        13 (72)                  9 (50)
  Number of respiratory hospitalizations in the last year   1.3 ± 2.5                0.7 ± 1.3
  Weeks since last use of prednisone/ antibiotic for COPD   19.7 ± 24.9              14.0 ± 17.6

**Note:** Values are expressed as the mean ± standard deviation or n (%).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; FVC, forced vital capacity.

###### 

Primary and secondary outcome results[\^](#tfn3-copd-8-097){ref-type="table-fn"}

                                                                         Placebo group (n = 18)      Vitamin D group (n = 18)   Difference (95% CI)
  ---------------------------------------------------------------------- --------------------------- -------------------------- ----------------------
  **Primary outcome**                                                                                                           
  SPPB baseline                                                          7.8 ± 1.6                   8.8 ± 1.8                  
  SPPB 6 weeks                                                           8.4 ± 2.6                   9.7 ± 1.2                  
  SPPB change (unadjusted)                                               0.6 ± 1.7 (−0.2 to 1.5)     0.9 ± 1.6 (0.1 to 1.8)     0.3 (−0.8 to 1.5)
  SPPB change (adjusted for baseline SPPB)                                                                                      0.6 (−0.5 to 1.8)
  **Secondary outcomes**                                                                                                        
  SGRQ total baseline[\*](#tfn4-copd-8-097){ref-type="table-fn"}         64 ± 15                     53 ± 18                    
  SGRQ total 6 weeks[\#](#tfn5-copd-8-097){ref-type="table-fn"}          63.8 ± 13.7                 55.6 ± 18.3                
  SGRQ change[∞](#tfn6-copd-8-097){ref-type="table-fn"} (unadjusted)     −1 ± 6.9 (−4.6 to 2.6)      1.3 ± 5.6 (−1.8 to 4.3)    2.3 (−2.3 to 6.9)
  SGRQ change (adjusted for baseline SGRQ)                                                                                      1.1 (−3.6 to 5.8)
  25(OH)D baseline,[\#](#tfn5-copd-8-097){ref-type="table-fn"} ng/mL     24.4 ± 10.5                 22.6 ± 10.5                
  25(OH)D at 6 weeks,[\#](#tfn5-copd-8-097){ref-type="table-fn"} ng/mL   22.1 ± 10.1                 32.6 ± 8.2                 
  25(OH)D change,[\#](#tfn5-copd-8-097){ref-type="table-fn"} ng/mL       −1.8 ± 3.1 (−3.4 to −0.3)   8.7 ± 5.5 (5.7 to 11.6)    10.5 (7.43 to 13.61)

**Notes:**^\^^Data available for 36 patients unless otherwise stated;

data available for 33 patients;

data available for 34 patients;

data available for 32 patients. Data are expressed as the mean ± standard deviation (95% CI).

**Abbreviations:** CI, confidence interval; SPPB, Short Physical Performance Battery; SGRQ, St George's Respiratory Questionnaire; 25(OH)D, serum 25-hydroxyvitamin D level.
